{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:13:36Z","timestamp":1789568016419,"version":"build-2803163510"},"reference-count":43,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"the Special Survey Service for Population Size Estimation of HIV High-Risk Groups","award":["250072955"],"award-info":[{"award-number":["250072955"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Men who have sex with men (MSM) face a high risk of HIV acquisition globally. Oral pre-exposure prophylaxis (PrEP) is effective but limited by adherence and stigma. Long-acting injectable PrEP (LAI-PrEP) offers a promising alternative, yet global acceptance among MSM remains unclear. This study aimed to estimate the pooled willingness to use LAI-PrEP among MSM and identify key determinants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, Web of Science, and CINAHL were searched up to March 26, 2026. The search strategy contained the keyword willingness and interest and the MeSH terms for MSM and PrEP. Data analysis was performed using R. The systematic review has been registered with PROSPERO (CRD420261432493).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirteen cross-sectional studies involving a total of 11,750 participants were included in the review. The pooled willingness rate was 69.9% (95% CI: 62.9%\u201376.9%). The test for subgroup differences showed no statistically significant difference among regions (\n                      <jats:italic toggle=\"yes\">\u03c7<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic toggle=\"yes\">2<\/jats:italic>\n                      <\/jats:sup>\n                      = 0.46,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.686). Six variables were significantly associated with higher willingness to use LAI-PrEP (all\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.05): oral PrEP use experience (OR = 2.67), history of HIV testing (OR = 1.99), engagement in transactional sex (OR = 1.79), having two or more male sexual partners in the past 6\u00a0months (OR = 1.74), heard of PrEP (OR = 2.13), and awareness of post-exposure prophylaxis (PEP) (OR = 1.67).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Willingness to use LAI-PrEP among MSM was high, but a substantial proportion expressed unwillingness. Therefore, we recommend integrated education campaigns, leveraging HIV testing as an entry point, and prioritizing high-risk subgroups for targeted LAI-PrEP promotion to optimize HIV prevention in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09564624261486907","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:33:28Z","timestamp":1789439608000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Willingness to use long-acting injectable HIV pre-exposure prophylaxis (PrEP) among men who have sex with men: A meta-analysis"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5752-0392","authenticated-orcid":false,"given":"Yao","family":"Song","sequence":"first","affiliation":[{"name":"Wuhan (Hanyang District Institute of Health Supervision, Wuhan)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songjie","family":"Wu","sequence":"additional","affiliation":[{"name":"Wuhan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqi","family":"Guo","sequence":"additional","affiliation":[{"name":"Wuhan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongdong","family":"Li","sequence":"additional","affiliation":[{"name":"Wuhan (Hanyang District Institute of Health Supervision, Wuhan)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Xia","sequence":"additional","affiliation":[{"name":"Wuhan (Hanyang District Institute of Health Supervision, Wuhan)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisha","family":"Wu","sequence":"additional","affiliation":[{"name":"Wuhan (Hanyang District Institute of Health Supervision, Wuhan)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Xin","sequence":"additional","affiliation":[{"name":"Wuhan (Hanyang District Institute of Health Supervision, Wuhan)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yu","sequence":"additional","affiliation":[{"name":"Wuhan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Hu","sequence":"additional","affiliation":[{"name":"Quality and Information Department, Wuhan Center for Disease Control and Prevention"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/20503121221113938"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtbi.2023.111635"},{"key":"e_1_3_6_4_2","unstructured":"UNAIDS. Global HIV & AIDS statistics \u2014 fact sheet. 2025. Available from: https:\/\/www.unaids.org\/en\/resources\/fact-sheet"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e32833a6c32"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjph-2023-000809"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17025"},{"key":"e_1_3_6_8_2","volume-title":"Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV","year":"2015","unstructured":"Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. World Health Organization; 2015."},{"key":"e_1_3_6_9_2","unstructured":"Guidance on pre-exposure oral prophylaxis (PrEP) for serodiscordant couples men and transgender women who have sex with men at high risk of HIV: Recommendations for use in the context of demonstration projects. World Health Organization; 2012."},{"key":"e_1_3_6_10_2","volume-title":"AVAC Regulatory status of TDF FTC for PrEP","year":"2019","unstructured":"AVAC Regulatory status of TDF FTC for PrEP. 2019. Available from."},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(22)00030-3"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2022.2135699"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.70068"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00261-8"},{"key":"e_1_3_6_15_2","volume-title":"Country planning for product introduction matrix","author":"AVAC","year":"2026","unstructured":"AVAC. Country planning for product introduction matrix, 2026."},{"key":"e_1_3_6_16_2","volume-title":"FDA approval of injectable lenacapavir marks progress for HIV prevention","author":"Organization WH","year":"2026","unstructured":"Organization WH. FDA approval of injectable lenacapavir marks progress for HIV prevention. 2026."},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411858"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407001"},{"key":"e_1_3_6_19_2","article-title":"User-reported outcomes of long-acting injectable PrEP with Cabotegravir: Real-world experience from Milan","author":"Raccagni AR","year":"2025","unstructured":"Raccagni AR, Passini F, Lolatto R, et al. User-reported outcomes of long-acting injectable PrEP with Cabotegravir: Real-world experience from Milan. HIV Med 2025.","journal-title":"HIV Med"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-025-26025-5"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/09564624211060824"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.70061"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0293297"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1521\/aeap.2025.37.6.427"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2023.0109"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-083837"},{"key":"e_1_3_6_28_2","first-page":"513","article-title":"High interest in long-acting injectable pre-exposure prophylaxis (LAI-PrEP) for HIV prevention among men who have sex with men (MSM): result from A Nationwide Survey in Malaysia","volume":"48","author":"Paudel K","year":"2023","unstructured":"Paudel K, Gupta S, Gautam K, et al. High interest in long-acting injectable pre-exposure prophylaxis (LAI-PrEP) for HIV prevention among men who have sex with men (MSM): result from A Nationwide Survey in Malaysia. J Consum Health Internet 2023; 48: 513\u2013521. https:\/\/doi.org\/10.1007\/s10900-023-01195-8","journal-title":"J Consum Health Internet"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1080\/00224499.2018.1449190"},{"key":"e_1_3_6_30_2","unstructured":"Meyers1 K Rodriguez1 K Moeller R W et al. High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy pp. 1\u201316."},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2024.2307378"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10508-024-02886-6"},{"key":"e_1_3_6_33_2","unstructured":"Levy M E Patrick R Gamble J et al. Willingness of community-recruited men who have sex with men in Washington DC to use long-acting injectable HIV pre-exposure prophylaxis. :1\u201314."},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-017-1845-z"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16142620"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-023-04197-8"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25883"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003754"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-023-04197-8"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2025.09.005"},{"key":"e_1_3_6_41_2","volume-title":"Policy brief: long-acting injectable cabotegravir for HIV pre-exposure prophylaxis","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. Policy brief: long-acting injectable cabotegravir for HIV pre-exposure prophylaxis. WHO, 2022."},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.1080\/00224499.2018.1449190"},{"key":"e_1_3_6_43_2","first-page":"513","article-title":"High interest in long-acting injectable pre-exposure prophylaxis (LAI-PrEP) for HIV prevention among men who have sex with men (MSM): result from A Nationwide Survey in Malaysia","volume":"48","author":"Paudel K","year":"2023","unstructured":"Paudel K, Gupta S, Gautam K, et al. High interest in long-acting injectable pre-exposure prophylaxis (LAI-PrEP) for HIV prevention among men who have sex with men (MSM): result from A Nationwide Survey in Malaysia. J Consum Health Internet 2023; 48: 513\u2013521. https:\/\/doi.org\/10.1007\/s10900-023-01195-8","journal-title":"J Consum Health Internet"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2022.0198"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624261486907","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09564624261486907","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624261486907","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:49:13Z","timestamp":1789566553000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09564624261486907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":43,"alternative-id":["10.1177\/09564624261486907"],"URL":"https:\/\/doi.org\/10.1177\/09564624261486907","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"article-number":"09564624261486907"}}